Abstract
IntroductionHuman multipotent mesenchymal stem cell (MSC) therapies are being tested clinically for a variety of disorders, including Crohn's disease, multiple sclerosis, graft-versus-host disease, type 1 diabetes, bone fractures, and cartilage defects. However, despite the remarkable clinical advancements in this field, most applications still use traditional culture media containing fetal bovine serum. The ill-defined and highly variable nature of traditional culture media remains a challenge, hampering both the basic and clinical human MSC research fields. To date, no reliable serum-free medium for human MSCs has been available.MethodsIn this study, we developed and tested a serum-free growth medium on human bone marrow-derived MSCs through the investigation of multiple parameters including primary cell isolation, multipassage expansion, mesoderm differentiation, cellular phenotype, and gene-expression analysis.ResultsSimilar to that achieved with traditional culture medium, human MSCs expanded in serum-free medium supplemented with recombinant human platelet-derived growth factor-BB (PDGF-BB), basic fibroblast growth factor (bFGF), and transforming growth factor (TGF)-β1 showed extensive propagation with retained phenotypic, differentiation, and colony-forming unit potential. To monitor global gene expression, the transcriptomes of bone marrow-derived MSCs expanded under serum-free and serum-containing conditions were compared, revealing similar expression profiles. In addition, the described serum-free culture medium supported the isolation of human MSCs from primary human marrow aspirate with continual propagation.ConclusionsAlthough the described serum-free MSC culture medium is not free of xenogeneic components, this medium provides a substitute for serum-containing medium for research applications, setting the stage for future clinical applications.
Highlights
Human multipotent mesenchymal stem cell (MSC) therapies are being tested clinically for a variety of disorders, including Crohn’s disease, multiple sclerosis, graft-versus-host disease, type 1 diabetes, bone fractures, and cartilage defects
Similar to that achieved with traditional culture medium, human MSCs expanded in serum-free medium supplemented with recombinant human platelet-derived growth factor-BB (PDGF-BB), basic broblast growth factor, and transforming growth factor (TGF)-β1 showed extensive propagation with retained phenotypic, di erentiation, and colony-forming unit potential
MSCs were expanded in a serum-containing growth medium (SCM) consisting of low-glucose DMEM supplemented with 10% MSCQualified Fetal Bovine Serum (FBS), 2 mmol/L l-gluta mine, and 5 μg/ml gentamicin to passage 4, where equal numbers of MSCs from each donor were combined into a single MSC donor pool and cryopreserved at 1.0 × 106 cells/ml (0.5 ml/vial) in complete SCM supplemented with 10% dimethyl sulfoxide (DMSO)
Summary
Human multipotent mesenchymal stem cell (MSC) therapies are being tested clinically for a variety of disorders, including Crohn’s disease, multiple sclerosis, graft-versus-host disease, type 1 diabetes, bone fractures, and cartilage defects. Despite the remarkable clinical advancements in this eld, most applications still use traditional culture media containing fetal bovine serum. The ill-de ned and highly variable nature of traditional culture media remains a challenge, hampering both the basic and clinical human MSC research elds. No reliable serum-free medium for human MSCs has been available
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
